CJC-1295 DAC: Complete Research Guide

Introduction: What is CJC-1295 DAC?

CJC-1295 DAC (Drug Affinity Complex) is a synthetic growth hormone-releasing hormone (GHRH) analog that has become increasingly popular in research and athletic communities. The “DAC” modification—a drug affinity complex using lysine—extends the peptide’s half-life from minutes to days, making it significantly more practical for research applications than earlier GH-releasing peptides. This comprehensive guide explores the mechanism of action, research findings, reconstitution protocols, storage requirements, and practical considerations for researchers working with CJC-1295 DAC.

Mechanism of Action: How CJC-1295 DAC Works

GHRH Receptor Signaling

CJC-1295 DAC functions by binding to GHRH receptors in the anterior pituitary gland. GHRH (growth hormone-releasing hormone) is a natural peptide hormone that stimulates the synthesis and secretion of growth hormone (GH). CJC-1295 DAC acts as a synthetic GHRH analog, mimicking this signaling cascade.

When CJC-1295 DAC binds to pituitary GHRH receptors, it initiates a cascade of intracellular signaling through G-protein coupled receptor (GPCR) pathways. This leads to increased cAMP levels, activation of protein kinase A (PKA), and ultimately increased gene transcription for growth hormone production and release.

The DAC Modification: Extended Half-Life

The critical innovation of CJC-1295 DAC is the Drug Affinity Complex modification. Native GHRH peptides are rapidly degraded by dipeptidyl peptidase-4 (DPP-4) enzymes in circulation, resulting in a half-life of just 7-15 minutes. The DAC modification involves conjugation with a lysine-based complex that creates an affinity binding to serum albumin.

This albumin-binding characteristic dramatically extends the peptide’s circulating half-life to approximately 6-8 days. The extended half-life means:

• Less frequent dosing required (typically once per week vs. multiple times daily)
• More stable and predictable GH secretion patterns
• Improved convenience for long-term research protocols
• Reduced handling and reconstitution frequency

Pulsatile vs. Continuous GH Release

CJC-1295 DAC stimulates GH release in a more physiologically relevant pulsatile pattern compared to continuous infusion methods. Natural GH secretion occurs in distinct pulses, typically 5-7 times daily, with the largest pulse occurring during sleep. CJC-1295 DAC helps preserve this pulsatile pattern, which is thought to be important for optimal metabolic effects.

Research Studies: What the Literature Shows

Human Clinical Data

Limited human clinical data exists for CJC-1295 DAC, as most research remains in pre-clinical stages. However, published studies show:

• Growth Hormone Stimulation: Multiple studies demonstrate 2-10 fold increases in GH secretion following CJC-1295 DAC administration, with effects persisting for extended periods due to the extended half-life.
• IGF-1 Production: As GH levels increase, hepatic production of insulin-like growth factor 1 (IGF-1) increases correspondingly. IGF-1 is considered the primary mediator of GH’s anabolic effects.
• Safety Profile: Early human studies indicate generally good tolerability, with most adverse events being mild and transient (injection site reactions, headache, facial flushing).
• Dosage Response: Research suggests a dose-dependent response, with 100 mcg appearing to be a commonly used research dose in published literature.

Pre-Clinical and Animal Research

Animal models have shown CJC-1295 DAC to effectively stimulate GH release and support anabolic tissue development. Effects studied include bone mineral density improvements, lean tissue accretion, and metabolic parameter changes. However, direct translation from animal to human research remains an active area of investigation.

CJC-1295 DAC Products at CertaPeptides

We offer two dosage strengths of pharmaceutical-grade CJC-1295 DAC:

• CJC-1295 DAC 2mg (Product ID: 206) — €24.99
• CJC-1295 DAC 5mg (Product ID: 207) — €44.99

Both products are supplied as lyophilized (freeze-dried) powder in sterile glass vials. All CertaPeptides products include a Certificate of Analysis (COA) detailing purity, potency, and microbial testing.

Reconstitution Protocol for CJC-1295 DAC

Materials Needed

• CJC-1295 DAC lyophilized powder vial
• Bacteriostatic water (0.9% sodium chloride + 0.9% benzyl alcohol) — see our bacteriostatic water products
• Sterile insulin syringe (25-30 gauge)
• Sterile alcohol prep pads
• Sterile filter needle (optional, recommended)

We recommend our Peptide Mixing Kit which includes most of these supplies.

Step-by-Step Reconstitution

Step 1: Prepare Your WorkspaceClean your workspace thoroughly with 70% isopropyl alcohol. Wash hands and consider using sterile gloves. Proper aseptic technique is critical for maintaining peptide sterility and stability.

Step 2: Calculate Reconstitution VolumeStandard research practice uses 1 mL of bacteriostatic water per 100 mcg of peptide. For example:- 2mg (2000 mcg) vial: reconstitute with 20 mL bacteriostatic water = 100 mcg/mL- 5mg (5000 mcg) vial: reconstitute with 50 mL bacteriostatic water = 100 mcg/mLThis creates a convenient dosing concentration of 100 mcg per 1 mL withdrawal.

Step 3: Draw Bacteriostatic WaterUsing a sterile syringe, draw up the calculated volume of bacteriostatic water. If using a filter needle, attach it now.

Step 4: Prepare the Peptide VialClean the rubber septum of the CJC-1295 DAC vial with a sterile alcohol prep pad. Allow 30 seconds for the alcohol to evaporate (do not blow on the vial).

Step 5: Inject Bacteriostatic WaterSlowly inject the bacteriostatic water into the peptide vial, aiming the stream against the vial’s inside wall rather than directly onto the lyophilized powder. This minimizes foaming and protein denaturation.

Step 6: Allow DissolutionLet the vial sit for 2-3 minutes. The lyophilized powder will gradually dissolve. Do not shake vigorously—gentle swirling or rolling the vial between your palms aids dissolution without creating foam.

Step 7: Verify Complete DissolutionThe solution should be clear or slightly opalescent. Any visible particles indicate incomplete dissolution or contamination.

Step 8: Transfer and StorageOnce dissolved, you may withdraw doses as needed using a fresh sterile syringe, or transfer the entire dissolved peptide to sterile vials for multiple uses. See storage guidance below.

Storage and Stability: Maximizing Peptide Longevity

Lyophilized (Unreconstituted) Storage

Lyophilized CJC-1295 DAC is extremely stable when properly stored:

• Temperature: 2-8°C (refrigerator) is ideal. Room temperature storage (20-25°C) is acceptable short-term but will reduce shelf life.
• Light Protection: Store in the original amber/brown glass vial. Protect from direct sunlight and UV exposure.
• Humidity: Keep in a dry environment. Vacuum-sealed vials provide additional protection; silica desiccant packets help absorb moisture.
• Expected Shelf Life: 2-3 years when stored at 2-8°C; potentially 1-2 years at room temperature (though refrigeration is strongly preferred).

Reconstituted Solution Storage

Once dissolved in bacteriostatic water, CJC-1295 DAC stability decreases:

• Temperature: Must be stored at 2-8°C (refrigerator). Do not allow to freeze or exceed 25°C.
• Duration: Typically stable for 2-4 weeks in solution at 2-8°C, though some researchers report stability up to 8 weeks. Bacteriostatic water’s antimicrobial properties help extend this window.
• Container: Use sterile glass vials with rubber septa. Avoid plastic syringes for long-term storage as some plastics may interact with the peptide.
• Sterility: Always use sterile technique when reconstituting and withdrawing doses. Any contamination will significantly reduce shelf life.

Freeze-Thaw Considerations

Freezing reconstituted CJC-1295 DAC is not recommended. Ice crystal formation can damage the peptide structure. If frozen reconstituted solution must be used, allow it to thaw slowly at 2-8°C before use, and discard any solution that shows visible particulates or discoloration.

Dosing Guidelines for Research

While exact dosing protocols vary by research protocol, typical guidance for CJC-1295 DAC includes:

• Common Research Dose: 100-300 mcg administered once weekly or split into 2x per week dosing
• Administration Route: Subcutaneous injection (under the skin). Intramuscular injection may also be used but is less common.
• Injection Sites: Rotate between subcutaneous sites (abdomen, thigh, upper arm) to minimize local irritation and lipohypertrophy.
• Timing: Some research suggests timing injections in the evening may align better with natural GH secretion patterns, though this remains an active area of investigation.

Comparison: CJC-1295 DAC vs Other GH-Releasing Peptides

CertaPeptides also offers other growth hormone secretagogues. Here’s how they compare:

Peptide	Half-Life	Dosing Frequency	Receptor Target	Effects
CJC-1295 DAC	6-8 days	1x per week	GHRH receptor	Sustained GH release
Ipamorelin	2 hours	3x daily	Ghrelin receptor	Pulsatile GH release
GHRP-6	30-45 minutes	3-4x daily	Ghrelin receptor	Potent GH release (includes appetite effects)

For a detailed comparison, see our guide Ipamorelin Research: Growth Hormone Secretagogue.

Frequently Asked Questions

How long does CJC-1295 DAC take to work?

Peak GH levels are typically observed 30-60 minutes after injection. The extended half-life means GH elevation persists for days. Some research suggests steady-state GH elevation builds over several weeks of repeated dosing.

Can CJC-1295 DAC be combined with other peptides?

Yes. CJC-1295 DAC is commonly stacked with Ipamorelin or other GHRP peptides to potentiate GH release. See our Research Peptide Stacks guide for more details.

What is a Certificate of Analysis (COA)?

A COA is a quality assurance document detailing purity, potency, and microbial testing. All CertaPeptides products include a COA. Learn how to read one in our How to Read a COA guide.

Is CJC-1295 DAC legal?

CJC-1295 DAC is sold for research purposes only. Researchers are responsible for understanding local regulations governing peptide research in their jurisdiction. See our Research Peptide Regulations in Europe 2026 guide.

Conclusion

CJC-1295 DAC represents a significant advancement in GH-releasing peptide research, offering extended half-life, convenient dosing, and sustained GH stimulation. Proper reconstitution, storage, and handling are critical to maximizing efficacy and maintaining peptide integrity. Whether used as a standalone research tool or as part of a peptide stack, CJC-1295 DAC remains a cornerstone of growth hormone research protocols.

For questions about product selection or reconstitution protocols, visit our FAQ or contact our research support team.